Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Pegaspargase, and Anlotinib in Stage IV NK/T-cell Lymphoma
NCT04004572Phase 2Completed
- Start
- Jul 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in natural killer/T-cell lymphoma (NKTL). Started Jul 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT04004572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004572.